Mechanisms of bariatric surgery and implications for the development of endoluminal therapies for obesity

Gastrointestinal Endoscopy

Volumn 70, Issue 6, 2009, Pages 1167-1175

  Stylopoulos, Nicholas ^a   Aguirre, Vincent ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE; PEPTIDE YY;

BALLOON; BARIATRIC SURGERY; BEHAVIOR THERAPY; BILIOPANCREATIC BYPASS; CLINICAL EFFECTIVENESS; GASTRECTOMY; GASTRIC BANDING; GASTROPLASTY; HUMAN; INSTRUMENT VALIDATION; JEJUNOILEAL BYPASS; LIFESTYLE MODIFICATION; MINIMALLY INVASIVE PROCEDURE; MOLECULAR MECHANICS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; STOMACH TUBE; SURGICAL ANATOMY; SURGICAL STAPLING; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

BARIATRIC SURGERY; GASTROPLASTY; HUMANS; OBESITY;

EID: 70949086371     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2009.01.022     Document Type: Review

References (66)

1. Haslam D.W., and James W.P. Obesity. Lancet 366 (2005) 1197-1209
2. Eckel R.H. Nonsurgical management of obesity in adults. N Engl J Med 358 (2008) 1941-1950
3. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
4. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 142 (2005) 547-559
5. Colquitt J., Clegg A., Loveman E., et al. Surgery for morbid obesity. Cochrane Database Syst Rev (2005) CD003641
6. Sjostrom L., Narbo K., Sjostrom D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752
7. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357 (2007) 753-761
8. Mun E.C., Blackburn G.L., and Matthews J.B. Current status of medical and surgical therapy for obesity. Gastroenterology 120 (2001) 669-681
9. Gumbs A.A., Gagner M., Dakin G., et al. Sleeve gastrectomy for morbid obesity. Obes Surg 17 (2007) 962-969
10. Stunkard A., and Laren-Hume M. The results of treatment for obesity: a review of the literature and report of a series. Arch Intern Med 103 (1959) 79-85
11. Mark A.L. Dietary therapy for obesity is a failure and pharmacotherapy is the future: a point of view. Clin Exp Pharmacol Physiol 33 (2006) 857-862
12. Kramer F.M., Jeffrey R.W., Forster J.L., et al. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 13 (1989) 123-136
13. Wadden T.A., and Butryn M.L. Behavioral treatment of obesity. Endocrinol Metab Clin North Am 32 (2003) 981-1003
14. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: description of lifestyle intervention. Diabetes Care 25 (2002) 2165-2171
15. Brownell K.D. The LEARN program for weight management (2000), American Health Publishing, Dallas (Tex)
16. Wadden T.A., Butryn M.L., and Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 132 (2007) 2226-2238
17. Rucker D., Padwal R., Li S.K., et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335 (2007) 1194-1199
18. The LOOK AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 30 (2007) 1374-1383
19. Foster G.D., Makris A.P., and Bailer B.A. Behavioral treatment of obesity. Am J Clin Nutr 82 (2005) 230S-235S
20. Padwal R., Rucker D., Li S., et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Syst Rev (2003) CD004094
21. Christensen R., Kristensen P.K., Bartels E.M., et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 371 (2007) 1706-1713 erratum, Lancet 2008;371:558
22. The European Medicines Agency recommends suspension of the marketing authorization of Acomplia [press release]. European Medicines Agency: Doc. Ref. EMEA/CHMP/537777/2008 (October 23, 2008). http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf Accessed December 7, 2008
23. Hofbauer K.G., Nicholson J.R., and Boss O. The obesity epidemic: current and future pharmacologic treatments. Annu Rev Pharmacol Toxicol 47 (2007) 565-592
24. Arterburn D.E., Crane P.K., and Veenstra D.L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164 (2004) 994-1003
25. McNeely W., and Benfield P. Orlistat. Drugs 52 (1998) 241-249
26. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166 (2002) 1307-1308
27. Tessier D.J., and Eagon J.C. Surgical management of morbid obesity. Curr Probl Surg 45 (2008) 68-137
28. Elder K.A., and Wolfe B.M. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 132 (2007) 2253-2271
29. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 55 (1992) 615S-619S
30. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
31. Surgery ASMBS. Metabolic surgery expected to play bigger role in treating type 2 diabetes and other metabolic diseases [press release]. Gainesville, Florida; August 22, 2007. Available at: http://www.asbs.org/Newsite07/resources/press_release_8202007.pdf. Accessed December 4, 2008.
32. Zhao Y., and Encinosa W. Bariatric surgery utilization and outcomes in 1998 and 2004: statistical brief no. 23. Rockville (Md): Agency for Healthcare Research and Quality (2007). http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.pdf Accessed December 4, 2008
33. Bult M.J., Van Dalen T., and Muller A.F. Surgical treatment for obesity. Eur J Endocrinol 158 (2008) 135-145
34. Dixon A.F.R., Dixon J.B., and O'Brien P.E. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90 (2005) 813-819
35. Sclafani A. Appetitive behavior after jejunoileal bypass. Int J Obes 5 (1981) 449-455
36. Bray G.A., Barry R.E., Benfield J.R., et al. Intestinal bypass surgery for obesity decreases food intake and taste preferences. Am J Clin Nutr 29 (1976) 779-783
37. Nishie A., Brown B., Barlon T., et al. Comparison of size of proximal gastric pouch and short-term weight loss following routine upper gastrointestinal contrast study after laparoscopic Roux-en-Y gastric bypass. Obes Surg 17 (2007) 1183-1188
38. Madan A.K., Tichansky D.S., and Phillips J.C. Does pouch size matter?. Obes Surg 17 (2007) 317-320
39. O'Connor E.A., and Carlin A.M. Lack of correlation between variation in small volume gastric pouch size and weight loss after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 4 (2008) 399-403
40. Roberts K., Duffy A., Kaufman J., et al. Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 21 (2007) 1397-1402
41. Christou N.V., Sampalis J.S., Liberman M., et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 240 (2004) 416-423
42. Pories W.J., Swanson M.S., MacDonald K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222 (1995) 339-350
43. Ballantyne G.H., Gumbs A., and Modlin I.M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of adipocytokines, leptin, adiponectin, and resistin. Obes Surg 15 (2005) 692-699
44. Rubino F., and Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236 (2002) 554-559
45. Thirlby R.C., Bahiraei F., Randall J., et al. Effect of Roux-en-Y gastric on satiety and food likes: the role of genetics. J Gastrointest Surg 10 (2006) 270-277
46. Burgmer R., Grigutsch K., Zipfel S., et al. The influence of eating behavior and eating pathology on weight loss after gastric restriction operations. Obes Surg 15 (2005) 684-691
47. Delin C.R., Watts J.M., Aebel J.L., et al. Eating behavior and the experience of hunger following gastric bypass surgery for morbid obesity. Obes Surg 7 (1997) 405-413
48. Bose M., Oliván B., and Texiera J. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?. Obes Surg 19 (2009) 217-229
49. Cummings D.E., Overduin J., and Foster-Schubert K.E. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89 (2004) 2608-2615
50. Morinigo R., Vidal J., Lacy A.M., et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery for morbidly obese subjects. Ann Surg 247 (2008) 270-275
51. Le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 (2007) 780-785
52. Cummings D.E. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss?. J Clin Endocrinol Metab 88 (2003) 2999-3002
53. Le Roux C.W., Aylwin S.J., Batterham R.L., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 (2006) 108-114
54. Schauer P., Chand B., and Brethauer S. New applications for endoscopy: the emerging field of endoluminal and transgastric surgery. Surg Endosc 21 (2007) 347-356
55. Fernandes M., Atallah A.N., Soares B.G.O., et al. Intragastric balloon for obesity. Cochrane Database Syst Rev (2007) CD004931
56. Dumonceau J.M. Evidence-based review of the Bioenterics Intragastric Balloon for weight loss. Obes Surg 18 (2008) 1611-1617
57. Fogel R., De Fogel J., Bonilla Y., et al. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1 year follow-up in 64 patients. Gastrointest Endosc 68 (2008) 51-58
58. Devière J., Ojeda Valdes G., Cuevas Herrera L., et al. Safety, feasibility, and weight loss after transoral gastroplasty: first human multicenter study. Surg Endosc 22 (2008) 589-598
59. Moreno C., Closset J., Dugardeyn S., et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy 40 (2008) 406-413
60. Rodriguez-Grunert L., Neto M.P.G., Alamo M., et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 4 (2008) 55-59
61. Gersin K.S., Keller J.E., Stefanidis D., et al. Duodenal-jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov 14 (2007) 275-278
62. Aguirre V., Stylopoulos, Grinbaum R., et al. An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity 16 (2008) 2585-2592
63. Strader A.D., Vahl T.P., Jandacek R.J., et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288 (2005) 447-453
64. Rubino F., Forgione A., Cummings D.E., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244 (2006) 741-749
65. Tarnoff M., Shikora S., and Lembo A. Acute technical feasibility of an endoscopic duodenal-jejunal bypass sleeve in a porcine model: a potentially novel treatment for obesity and type 2 diabetes. Surg Endosc 22 (2008) 772-776
66. Tarnoff M., Shikora S., Lembo A., et al. Chronic in vivo experience with an endoscopically delivered and retrieved duodenal-jejunal bypass sleeve in a porcine model. Surg Endosc 22 (2008) 1023-1028